Capital Advisors Inc. OK Sells 155 Shares of Edwards Lifesciences Co. (NYSE:EW)

Capital Advisors Inc. OK reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,869 shares of the medical research company’s stock after selling 155 shares during the period. Capital Advisors Inc. OK’s holdings in Edwards Lifesciences were worth $829,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of EW. Louisiana State Employees Retirement System acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $2,798,000. Simplicity Solutions LLC increased its holdings in Edwards Lifesciences by 27.5% during the fourth quarter. Simplicity Solutions LLC now owns 15,112 shares of the medical research company’s stock worth $1,152,000 after buying an additional 3,255 shares during the last quarter. Baystate Wealth Management LLC bought a new stake in Edwards Lifesciences during the fourth quarter worth $92,000. Seascape Capital Management lifted its stake in Edwards Lifesciences by 0.6% in the fourth quarter. Seascape Capital Management now owns 27,766 shares of the medical research company’s stock valued at $2,117,000 after acquiring an additional 170 shares during the last quarter. Finally, NewEdge Wealth LLC increased its stake in shares of Edwards Lifesciences by 17.1% during the 4th quarter. NewEdge Wealth LLC now owns 7,098 shares of the medical research company’s stock worth $541,000 after purchasing an additional 1,039 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, VP Daniel J. Lippis sold 1,715 shares of the stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the completion of the sale, the vice president now owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $90.98, for a total value of $156,030.70. Following the transaction, the vice president now directly owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total transaction of $944,130.00. Following the sale, the vice president now directly owns 39,503 shares of the company’s stock, valued at approximately $3,390,542.49. The disclosure for this sale can be found here. Insiders have sold 194,004 shares of company stock worth $17,166,254 in the last 90 days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW traded down $1.13 during midday trading on Friday, hitting $90.28. The company’s stock had a trading volume of 3,155,519 shares, compared to its average volume of 3,074,077. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12. The stock has a market capitalization of $54.34 billion, a price-to-earnings ratio of 39.25, a price-to-earnings-growth ratio of 4.47 and a beta of 1.05. The company’s fifty day simple moving average is $90.01 and its two-hundred day simple moving average is $77.74.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm’s revenue was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.64 EPS. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on EW shares. Royal Bank of Canada lifted their price target on Edwards Lifesciences from $82.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Truist Financial upped their price target on shares of Edwards Lifesciences from $78.00 to $84.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. Evercore ISI upped their target price on Edwards Lifesciences from $86.00 to $92.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Finally, Oppenheimer raised their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, March 18th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and an average target price of $91.33.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.